Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Munich - Delayed Quote EUR

Pfizer Inc (PFE.MU)

Compare
24.92
-0.23
(-0.91%)
At close: February 28 at 5:27:15 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
63,627,000
63,627,000
59,553,000
101,175,000
81,288,000
Cost of Revenue
17,851,000
17,851,000
24,954,000
34,344,000
30,821,000
Gross Profit
45,776,000
45,776,000
34,599,000
66,831,000
50,467,000
Operating Expense
30,838,000
30,838,000
30,183,000
28,714,000
26,763,000
Operating Income
14,938,000
14,938,000
4,416,000
38,117,000
23,704,000
Net Non Operating Interest Income Expense
-2,546,000
-2,546,000
-585,000
-987,000
-1,255,000
Other Income Expense
-4,369,000
-4,369,000
-2,774,000
-2,400,000
1,763,000
Pretax Income
8,023,000
8,023,000
1,058,000
34,729,000
24,311,000
Tax Provision
-28,000
-28,000
-1,115,000
3,328,000
1,852,000
Net Income Common Stockholders
8,031,000
8,031,000
2,119,000
31,372,000
21,979,000
Diluted NI Available to Com Stockholders
8,031,000
8,031,000
2,119,000
31,372,000
21,979,000
Basic EPS
0.76
1.42
0.38
5.59
3.92
Diluted EPS
0.75
1.41
0.37
5.47
3.85
Basic Average Shares
5,658,750
5,664,000
5,643,000
5,608,000
5,601,000
Diluted Average Shares
5,658,750
5,700,000
5,709,000
5,733,000
5,708,000
Total Expenses
48,689,000
48,689,000
55,137,000
63,058,000
57,584,000
Net Income from Continuing & Discontinued Operation
8,031,000
8,031,000
2,119,000
31,372,000
21,979,000
Normalized Income
12,237,810
12,237,810
5,997,890
35,038,952
24,999,276
Interest Income
545,000
545,000
1,624,000
251,000
36,000
Interest Expense
3,091,000
3,091,000
2,209,000
1,238,000
1,291,000
Net Interest Income
-2,546,000
-2,546,000
-585,000
-987,000
-1,255,000
EBIT
11,114,000
11,114,000
3,267,000
35,967,000
25,602,000
EBITDA
18,127,000
18,127,000
9,557,000
41,031,000
30,793,000
Reconciled Cost of Revenue
16,124,000
16,124,000
23,397,000
32,889,000
29,330,000
Reconciled Depreciation
7,013,000
7,013,000
6,290,000
5,064,000
5,191,000
Net Income from Continuing Operation Net Minority Interest
8,020,000
8,020,000
2,134,000
31,366,000
22,413,000
Total Unusual Items Excluding Goodwill
-5,339,000
-5,339,000
-4,891,000
-4,063,000
-2,799,000
Total Unusual Items
-5,339,000
-5,339,000
-4,891,000
-4,063,000
-2,799,000
Normalized EBITDA
23,466,000
23,466,000
14,448,000
45,094,000
33,592,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-1,121,190
-1,121,190
-1,027,110
-390,048
-212,724
12/31/2021 - 1/3/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

LLY.BE Eli Lilly and Co
863.50
-1.89%
 
LLY.HA Eli Lilly and Co
865.30
-0.98%
 
LLY.DU Eli Lilly and Co
866.90
-1.33%
 
LLY.SW Eli Lilly and Company
790.00
0.00%
 
LLY.SG Eli Lilly and Co
860.70
-1.16%
 
LLY.HM Eli Lilly and Co
865.30
-2.44%
 
LLY.BA Eli Lilly and Company
19,975.00
+1.14%
 
LLY0.F Eli Lilly and Company
21.20
-0.93%
 
4AB.F AbbVie Inc.
197.68
+2.16%
 
LLY.MX Eli Lilly and Company
18,656.00
+0.44%